The new COVID vaccine being developed
by Rome biotech company ReiThera is safe, a Spallanzani
infectious disease hospital official said on Tuesday.
Giuseppe Ippolito, scientific director at Italy's premier
infectious disease hospital, was speaking at the presentation of
the results of Phase One of testing of the GRAd-CoV2 vaccine
made by ReiThera, which is based at Castel Romano on the
outskirts of the Italian capital.
Ippolito said "we enrolled 100 people and 45 were vaccinated
with different doses and all arrived at the end for the safety
assessment: the vaccine did not have any serious adverse effect
in the first 28 days from the vaccination, a better result
compared to Moderna and Pfizer which had undesired effects.
"The peak of production of antibodies remains constant at four
weeks and the vaccine is single dose".
The new vaccine developed anti-bodies in 92.5% of those tested,
Ippolito added.
ReiThera President Antonella Folgore said the company was aiming
to produce 100 million doses of vaccine per year.
He said the vaccine was stable at a temperature of between two
and eight degrees Celsius.
Italy's COVID commissioner, Domenico Arcuri, said that "with
ReiThera Italy is aiming for vaccine independence".
ALL RIGHTS RESERVED © Copyright ANSA
